Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Targeting prostate cancer based on signal transduction and cell cycle pathways.

Lee JT, Lehmann BD, Terrian DM, Chappell WH, Stivala F, Libra M, Martelli AM, Steelman LS, McCubrey JA.

Cell Cycle. 2008 Jun 15;7(12):1745-62. Epub 2008 Jun 16. Review.

2.

Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.

Choi HJ, Chung TW, Kang SK, Lee YC, Ko JH, Kim JG, Kim CH.

Glycobiology. 2006 Jul;16(7):573-83. Epub 2006 Mar 30.

PMID:
16574813
3.
4.
5.

Influence of zinc deficiency on Akt-Mdm2-p53 and Akt-p21 signaling axes in normal and malignant human prostate cells.

Han CT, Schoene NW, Lei KY.

Am J Physiol Cell Physiol. 2009 Nov;297(5):C1188-99. doi: 10.1152/ajpcell.00042.2009. Epub 2009 Aug 5.

PMID:
19657064
6.

Multiple defects in negative regulation of the PKB/Akt pathway sensitise human cancer cells to the antiproliferative effect of non-steroidal anti-inflammatory drugs.

Lincová E, Hampl A, Pernicová Z, Starsíchová A, Krcmár P, Machala M, Kozubík A, Soucek K.

Biochem Pharmacol. 2009 Sep 15;78(6):561-72. doi: 10.1016/j.bcp.2009.05.001. Epub 2009 May 9.

PMID:
19433066
7.

7-epi-nemorosone from Clusia rosea induces apoptosis, androgen receptor down-regulation and dysregulation of PSA levels in LNCaP prostate carcinoma cells.

Díaz-Carballo D, Gustmann S, Acikelli AH, Bardenheuer W, Buehler H, Jastrow H, Ergun S, Strumberg D.

Phytomedicine. 2012 Nov 15;19(14):1298-306. doi: 10.1016/j.phymed.2012.08.004. Epub 2012 Sep 14.

PMID:
22981203
8.

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.

Adv Enzyme Regul. 2006;46:249-79. Epub 2006 Jul 18.

PMID:
16854453
9.

Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells.

Chinni SR, Li Y, Upadhyay S, Koppolu PK, Sarkar FH.

Oncogene. 2001 May 24;20(23):2927-36.

10.
11.

PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice.

Zheng T, Meng X, Wang J, Chen X, Yin D, Liang Y, Song X, Pan S, Jiang H, Liu L.

J Cell Biochem. 2010 Sep 1;111(1):218-28. doi: 10.1002/jcb.22691.

PMID:
20506484
12.

BCR signals target p27(Kip1) and cyclin D2 via the PI3-K signalling pathway to mediate cell cycle arrest and apoptosis of WEHI 231 B cells.

Banerji L, Glassford J, Lea NC, Thomas NS, Klaus GG, Lam EW.

Oncogene. 2001 Nov 1;20(50):7352-67.

13.

Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression.

Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, Paul JD, Hbaiu A, Goode RG, Sandusky GE, Vessella RL, Neubauer BL.

J Biol Chem. 2000 Aug 11;275(32):24500-5.

15.

PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells.

Itsumi M, Shiota M, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Inokuchi J, Tatsugami K, Uchiumi T, Naito S.

J Mol Endocrinol. 2014 Aug;53(1):31-41. doi: 10.1530/JME-13-0303. Epub 2014 Apr 29.

PMID:
24780839
16.

Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells.

Dixon KM, Lui GY, Kovacevic Z, Zhang D, Yao M, Chen Z, Dong Q, Assinder SJ, Richardson DR.

Br J Cancer. 2013 Feb 5;108(2):409-19. doi: 10.1038/bjc.2012.582. Epub 2013 Jan 3.

17.
18.

Inhibition of Akt pathways in the treatment of prostate cancer.

Nelson EC, Evans CP, Mack PC, Devere-White RW, Lara PN Jr.

Prostate Cancer Prostatic Dis. 2007;10(4):331-9. Epub 2007 May 1. Review.

PMID:
17471291
19.

Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.

Steelman LS, Navolanic P, Chappell WH, Abrams SL, Wong EW, Martelli AM, Cocco L, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, McCubrey JA.

Cell Cycle. 2011 Sep 1;10(17):3003-15. Epub 2011 Sep 1.

20.

Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.

Lin HP, Lin CY, Hsiao PH, Wang HD, Jiang SS, Hsu JM, Jim WT, Chen M, Kung HJ, Chuu CP.

PLoS One. 2013 Dec 5;8(12):e82625. doi: 10.1371/journal.pone.0082625. eCollection 2013.

Supplemental Content

Support Center